{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-164481","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.020575+00:00","generated_at":"2026-06-14T04:14:04.436586+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Ikena Oncology shareholders elect three Class II directors, ratify E&Y as auditor","bullets":["David Bonita (16.5M for, 7.6M against, 2.3M broker non-votes) elected to three-year term.","Jean-François Formela (20.8M for, 3.3M against) and Richard Wooster (20.8M for, 3.3M against) also elected.","Ernst & Young LLP ratified as independent auditor for FY2023 with 26.4M for, 9k against, 1.3k abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-164481","json":"https://secwatch.observer/filing/0001193125-23-164481.json","markdown":"https://secwatch.observer/filing/0001193125-23-164481.md","text":"https://secwatch.observer/filing/0001193125-23-164481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523164481/0001193125-23-164481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523164481/d483896d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T04:14:04.436586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7782bd5da9eda0594e407719a4d10c88ea01888e","claim":"ImageneBio, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-09 meeting.","evidence_excerpt":"The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 26,385,702 9,069 1,307 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523164481/0001193125-23-164481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"},{"claim_id":"e94ae11cd3a1296ccbbfa6e1cd600412a324b335","claim":"ImageneBio, Inc. shareholders approved Election of Class II Directors: David Bonita, M.D., Jean-François Formela, M.D., and Richard Wooster, Ph.D. at the 2023-06-09 meeting.","evidence_excerpt":"The votes cast at the Annual Meeting were as follows: For Withheld Broker Non-Votes David Bonita, M.D. 16,468,374 7,623,868 2,303,836 Jean-François Formela, M.D. 20,781,723 3,310,519 2,303,836 Richard Wooster, Ph.D. 20,784,244 3,307,998 2,303,836","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523164481/0001193125-23-164481-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}